User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

3625

Interactions with Platform & by Email *

INTERACTIONS

653

Unique # Participated *

PARTICIPANTS

109

Responses Validated *

VALIDATIONS

31

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Incidence and Prevalence of Diabetic Retinopathy Continue to Rise.....II-1 1$75
   Table 1: Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart).....II-2

Table 2: Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart).....II-2
1$350
   Table 3: Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart).....II-3
Prevalence of Diabetes on the Rise.....II-3
Huge Unmet Needs Fuel Demand for Pharmacological Drugs.....II-3
1$350
   Market Awaits First Approved Drug; Off-label Use Continues.....II-4
Diabetic Retinopathy Drug Market to Post Dramatic Growth.....II-4
Insulin – A Potential Therapy for Diabetic Retinopathy.....II-4
1$75
   Additional Trials Delay Arxxant’s Launch.....II-5
Lucentis Shows Promise in Diabetic Retinopathy Treatment.....II-5
1$75
   Avastin and Lucentis to Compete on Price.....II-6
Pycnogenol Continues to Appeal to Researchers.....II-6
1$75
   Robo4 Protein – A Potential Therapeutic for Diabetic Retinopathy.....II-7
Bevacizumab Bodes Potential As An Adjunct to Surgery PDR Treatment.....II-7
1$75
   Drug Classes in Diabetic Retinopathy.....II-8
VEGF Inhibitors.....II-8
Pegaptanib.....II-8
Bevacizumab.....II-8
Ranibizumab.....II-8
1$75
   PKC Inhibitors.....II-9
Corticosteroids.....II-9
1$75
   Aldose Reductase - AGE Inhibitors.....II-10
Somatostatin Analog.....II-10
1$75
   Other Pharmacological Therapeutic Agents.....II-111$75
   Select Pipeline Drugs in Diabetic Retinopathy Market.....II-12
An Overview of Select Pipeline Drugs.....II-12
Arxxant (Eli Lilly).....II-12
1$75
   Iluvien® (pSivida Corp.).....II-13
Atacand (AstraZeneca).....II-13
Lucentis (Genentech and Novartis).....II-13
1$75
   Avastin (Genentech/Roche).....II-14
Vitreosolve® (Vitreo Retinal Technologies).....II-14
Posurdex (Allergan).....II-14
Macugen (EyeTech).....II-14
1$75
   Cand5 (Opko Health, Inc.).....II-15
PF-4523655 (Quark Pharmaceuticals/Pfizer).....II-15
1$75
   Intravitreal Triamcinolone Acetonide (Allergan).....II-16
Peribulbar Triamcinolone Acetonide (Bristol Myers).....II-16
Microplasmin (ThromboGenics N.V.).....II-16
1$75
   Aflibercept (Regeneron/Bayer).....II-17
Sirolimus (MacuSight/Santen).....II-17
1$75
   iCo-007 (iCo Therapeutics).....II-18
Other Drugs with Potential Benefits in DR Treatment.....II-18
1$75
   Diabetes.....II-19
Quick Facts on Diabetes.....II-19
Diabetic Retinopathy.....II-19
1$75
   Leading Cause of Blindness in Diabetic Population.....II-20
Pathogenesis of Diabetic Retinopathy.....II-20
1$75
   Clinical Features.....II-21
Proliferative and Non-Proliferative Diabetic Retinopathy.....II-21
1$75
   Diabetic Macular Edema.....II-22
Risk Factors for the Condition.....II-22
2$100
   Symptoms.....II-24
Prevention of Diabetic Retinopathy.....II-24
1$75
   Detection of Proliferative Retinopathy and Macular Edema.....II-25
Visual Acuity Test.....II-25
Fundus Fluorescein Angiography.....II-25
Ophthalmoscopy.....II-25
1$75
   Optical Coherence Tomography.....II-26
Non-Mydriatic Fundus Photography.....II-26
Dynamics of Evaluating Technologies.....II-26
1$75
   Frequency of Examinations.....II-27
Treatment for Diabetic Retinopathy.....II-27
Laser Surgery.....II-27
1$75
   Scatter Laser Treatment/ Panretinal Photocoagulation.....II-28
Focal Laser Treatment/ Photocoagulation.....II-28
Vitrectomy.....II-28
1$75
   Kenalog/ Triamcinolone Actinomide.....II-291$75
   Sanofi-Aventis to Take Over Fovea Pharmaceuticals.....II-30
New Injectable Steroid In-Line from Wakamoto Pharmaceutical.....II-30
1$75
   Sirion Therapeutics and Advanced Vision Research Signs Agreement.....II-31
ActiveSite Develops Protease Inhibitor for Treating Diabetic Retinopathy.....II-31
Pipex Acquires Global License for Additional Usage of Oral Flupirtine.....II-31
1$75
   MacuSight and Santen Ink License Agreement.....II-32
OptiMedica Enters into Distribution Agreement with Topcon Medical.....II-32
1$75
   Lpath Submits IND for iSONEP™.....II-33
Iris Pharma Merges with Clirophtha.....II-33
1$75
   Isis Receives Milestone Payment for Initiating Trials of iCo-007.....II-34
Eli Lilly Withdraws Marketing Authorization Application for Arxxant in Europe.....II-34
ThromboGenics Begins Phase IIb Trial of Microplasmin in the US.....II-34
2$100
   Allergan, Inc. (US).....II-36
AstraZeneca PLC (UK).....II-36
Eyetech, Inc. (US).....II-36
Fovea Pharmaceuticals SA (France).....II-36
1$75
   Genentech, Inc. (US).....II-37
Gene Signal (Switzerland).....II-37
1$75
   Isis Pharmaceuticals, Inc. (US).....II-38
Lpath, Inc. (US).....II-38
1$75
   MacuSight, Inc. (US).....II-39
OM PHARMA S.A (Switzerland).....II-39
1$75
   OPKO Health, Inc. (US).....II-40
Oxford BioMedica Plc. (UK).....II-40
pSivida Corp. (US).....II-40
Quark Pharmaceuticals, Inc. (US).....II-40
1$75
   Sanwa Kagaku Kenkyusho Co., Ltd. (Japan).....II-41
Sirnaomics, Inc. (US).....II-41
1$75
   Suzuken Co., Ltd. (Japan).....II-42
Vitreoretinal Technologies, Inc. (US).....II-42
1$75
   Table 4: US Diabetic Retinopathy Drugs Market Potential: Annual Sales Forecasts in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-431$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com